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Objectives: Our objective was to analyze the impact of preoperative and
postresection solid tumor volumes on outcomes in 47 of 48 consecutive
patients undergoing resection for malignant pleural mesothelioma who
were treated prospectively and randomized to photodynamic therapy or no
photodynamic therapy. Methods: From July 1993 to June 1996, 48 patients
with malignant pleural mesothelioma had cytoreductive debulking to 5 mm
or less residual tumor by extrapleural pneumonectomy (n 5 25) or
pleurectomy/decortication (n 5 23). Three-dimensional computed tomo-
graphic reconstructions of preresection and postresection solid tumor were
prospectively performed and the disease was staged postoperatively accord-
ing to the new International Mesothelioma Interest Group staging. Results:
Median survival for all patients is 14.4 months (extrapleural pneumonec-
tomy, 11 months; pleurectomy/decortication, 22 months; p2 5 0.07). Median
survival for preoperative volume less than 100 was 22 months versus 11
months if more than 100 cc, p2 5 0.03. Median survival for postoperative
volume less than 9 cc was 25 months versus 9 months if more than 9 cc, p2 5
0.0002. Thirty-two of forty-seven (68%) had positive N1 or N2 nodes. Tumor
volumes associated with negative nodes were significantly smaller (median
51 cc) than those with positive nodes (median 166 cc, p2 5 0.01).
Progressively higher stage was associated with higher median preoperative
volume: stage I, 4 cc; stage II, 94 cc; stage III, 143 cc; stage IV, 505 cc; p2 5
0.007 for stage I versus II versus III versus IV. Patients with preoperative
tumor volumes greater than 52 cc had shorter progression-free intervals (8
months) than those 51 cc or less (11 months; p2 5 0.02). Conclusions:
Preresection tumor volume is representative of T status in malignant
pleural mesothelioma and can predict overall and progression-free sur-
vival, as well as postoperative stage. Large volumes are associated with
nodal spread, and postresection residual tumor burden may predict
outcome. (J Thorac Cardiovasc Surg 1998;115:310-8)
Malignant pleural mesothelioma (MPM) remainsa staging and management enigma to both
medical and thoracic surgical oncologists. The poor
survival and persistent local recurrences after oper-
ative therapy have led to a feeling of nihilism among
most thoracic surgeons, and no single agent or
combination chemotherapeutic regimens exist with
consistently higher partial response rates than 20%
in human trials.1 Multimodality trials have been
reported for MPM with reports of medians survivals
of 22 months; yet on closer scrutiny of these trials,
one finds that these are a select group of patients for
whom a “margin negative” resection can be accom-
plished, and most long-term survivors did not have
regional nodal spread.2
To resolve situations of treatment-result hetero-
geneity for a given neoplasm, it is important that a
consistent, uniformly adapted staging system be in
place. Ideally, the staging system would not require
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invasive techniques to identify prognostically unfa-
vorable subgroups. As described by Rusch, the five
staging systems before the International Mesotheli-
oma Interest Group (IMIG) Staging System have
“(been) to some extent imprecise and incompletely
validated.”3 The IMIG staging system has only
recently been available; at this writing it has only
been validated in one series of 131 patients4; and it
has not been prospectively evaluated with regard to
clinical versus operative stage.
Since 1993, a prospective randomized trial evalu-
ating the role of intraoperative photodynamic
therapy (PDT) in patients having operative cytore-
duction of MPM and postoperative immunochemo-
therapy has been conducted at our institution. In 47
of the 48, T status has been assessed as solid tumor
volume using a three-dimensional computerized to-
mographic reconstruction technique. Because no
differences in survival or recurrence patterns were
noted between the treatment arms in this completed
study,5 this study reports the prognostic variables
associated with the patients who had uniform cy-
toreduction to 5 mm thickness of residual tumor
independent of treatment group. Specifically, we
were interested in the possible association of volu-
metrics with survival and recurrence and volumetric
correlation with the new IMIG staging system as a
whole, as well as individualized components such as
nodal (N) status.
Methods
Patients were considered for the prospective random-
ized trial of surgery, intraoperative PDT, and immunoche-
motherapy versus surgery and postoperative immunoche-
motherapy if, on review of their chest computerized
tomogram before registration, it was believed that the
disease was amenable to a subtotal extirpation such that
the maximum thickness after debulking at any intratho-
racic site was 5 mm or less. From July 1993 to June 1996,
63 patients were registered and randomized for a Phase
III randomized trial investigating the use of intrapleural
PDT for MPM, which was approved by the National
Cancer Institute Institutional Review Board. There were
18 female and 45 male patients, all of whom signed
informed consent. Of these, 15 patients (3 female and 12
male patients) were not considered for the volumetric
analysis because of inability to debulk to the prerequisite
5 mm (eight patients, four PDT; four non-PDT), progres-
sion before operative intervention (six), or patient with-
drawal before resection (one).
Either pleurectomy decortication alone or in combina-
tion with anatomic or nonanatomic resection and ex-
trapleural pneumonectomy was performed, as long as the
cytoreductive criteria to 5 mm could be met. This was, for
most of the patients, a decision that was made at the time
of exploration unless lung function, as defined preopera-
tively with quantitative perfusion scanning, suggested that
the affected lung was essentially nonfunctional, which
implied that an extrapleural pneumonectomy would be
required to meet cytoreductive criteria. The extrapleural
pneumonectomy could be modified to include or not
include portions of the pericardium or diaphragm. All
patients having cytoreduction also had mediastinal nodal
dissection and recording of intraoperative descriptors,
some of which were later (1994) defined by the new IMIG
staging system.
All patients fulfilling criteria for cytoreduction received
postoperative immunochemotherapy (CIT) consisting of
two cycles of tamoxifen citrate (INN: tamoxifen), 20 mg
orally bid given every day for 35 days, interferon-a2B (5
mU/m2) delivered three times a week by subcutaneous
injection, and cisplatin (CDDP), 25 mg/m2, delivered on
days 8, 15, 22, and 29 at least 30 minutes after interferon
delivery.
Preoperative randomization determined whether the
patient would receive (n 5 23) or not receive (n 5 25)
intraoperative PDT at the time of maximal cytoreduction.
As previously reported,5 the following descriptors were
not statistically significantly different between the two
groups: age, symptoms, interval from symptoms/diagnosis
to treatment, performance status, pulmonary function,
tumor volume (preoperative or postoperative), type of
operation performed, histologic findings, involved nodes,
or postoperative IMIG stage. Moreover, median survival
and time to recurrence was virtually identical in compar-
ing both groups. Therefore the analysis of outcomes and
verification of the IMIG staging system were considered
for all patients (n 5 47) having complete intraoperative
staging data and preoperative volumetrics.
Preoperative and follow-up tumor volume determina-
tions. The volume of solid tumor (T status) was objec-
tively quantitated using the Voxel Scope II three-dimen-
sional Imaging Work Station (Picker International,
Highland Heights, Ohio) in 47 of the 48 patients having
cytoreduction. For each patient the tapes of the comput-
erized tomographic examinations were loaded into the
memory of the system, and serial images of each study
were depicted on the screen. One individual (B.T.) out-
lined the borders of the solid tumor using a hand-
controlled mouse, with discrimination of solid tumor from
fluid based on differences in tissue density. The system
then calculated the three-dimensional volume in cubic
centimeters of total solid tumor burden or of any desired
subset or fraction.
The volumetrics were performed before resection, be-
fore initiation of immunochemotherapy (pre CIT), at the
completion of CIT, and on follow-up examinations (every
3 months).
To compare the Voxell volumetric method for estimat-
ing size with more standard oncologic measures of tumor
size, tumor areas were calculated using the same comput-
erized tomograms in 43 of the patients. For each patient’s
scan, the individual slices (30 to 40 slices per scan) were
divided into four quadrants, and the perpendicular diam-
eters of solid tumor for each quadrant were recorded. The
total solid tumor area was then calculated as the cumula-
tive summation of the products of these perpendicular
diameters (i.e., the sum of 120 to 160 diameter products
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per patient) and correlated with the corresponding tumor
volume for that patient.
Statistical methods. Survival time and time to progres-
sion in months were calculated from date of surgery until
death, progression, or last follow-up as appropriate. The
probability of survival or progression was calculated using
the Kaplan-Meier method,6 and the significance of the
difference between pairs of Kaplan-Meier curves was
calculated using the Mantel-Haenszel procedure.7 The
Cox proportional hazards model was used to identify
which factors were jointly significant in the association
with survival or recurrence.8 The factors considered for
inclusion in univariate and Cox analyses were sex, histo-
logic type of MPM, pretreatment platelet counts, type of
operative procedure, nodal status, size (in cubic centime-
ters) before cytoreduction and pre CIT, and pathologic
IMIG stage. Only those factors that were associated with
at least a trend toward statistical significance in a univar-
iate analysis (p2 , 0.20) were ultimately evaluated in a
Cox model. Continuous parameters such as tumor size
were divided into quartiles; because the trends in survival
or recurrence-free survival were not necessarily linear
over the four quartiles, for the Cox models, the data
were dichotomized at the quartile that yielded the most
significant result in the univariate analysis. In the case
of preoperative tumor values, because a prior analysis
had demonstrated that 100 cc was a reasonable thresh-
old,9 this threshold was also considered for evaluation
in the Cox model in addition to a threshold based on a
division at a quartile. In view of the limited number of
patients in this study, these Cox models and the thresh-
olds used in parameters evaluated in the Cox models
were intended to be interpreted as hypothesis generat-
ing rather than definitive, with thresholds identified
intended to be suggestive of effect rather than absolute.
A backward selection algorithm was used to identify a
reasonable model to represent the associations of var-
ious parameters with outcome. The resulting model
parameters (bi) were converted to relative risks by
computing exp(bi), where exp(a) 5 2.7183
a. The 95%
confidence interval for the relative risk was computed
as [exp (biL), exp (biH)], where biL5bi-1.96 [estimated
standard error (bi)] and biH5bi11.96 [estimated stan-
dard error (bi)].
10 The relative risk indicates the risk
associated with dying or progressing while being in a
greater risk category compared with that of being in the
lowest risk category. For example, a risk of 2.0 indicates
twice the risk of dying during any interval if a patient
has the trait associated with elevated risk compared
with a patient without the trait. Jonckheere’s test for
trend11 was used to determine the significance of the
association between stage and preoperative volume,
whereas the Wilcoxon rank sum test compared sizes
according to nodal status. All p values are two-sided
and are denoted by p2.
Results
The median potential follow-up for the 47 pa-
tients was 23.1 months, with 29 of the 47 patients
dead from mesothelioma as of the last analysis. The
median survival for all patients was 14.4 months, and
a trend for longer survival was observed in patients
having pleurectomy/decortication compared with
patients having extrapleural pneumonectomy (22
months vs 11 months, p2 5 0.07). The mean
(6SEM) preoperative volume for patients having a
pleurectomy decortication was 88 6 16 cc vs 418 6
86 cc for extrapleural pneumonectomy (EPP) (p2 ,
0.0001). No difference was observed in preoperative
size (p2 5 0.70) in male patients (n 5 32, 267 6 64
Fig. 1. Influence of preoperative size on overall survival of patients having cytoreduction for malignant
pleural mesothelioma (p2 5 0.03)
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cc) compared with female patients (n 5 15, 257 6 92
cc).
In univariate analyses, nodal status and cell type
were not associated with survival (p2 . 0.20), but
cell type was moderately associated with recurrence-
free survival (p2 5 0.09), whereas nodal status was
not associated with recurrence-free survival (p 5
0.48). In the Cox model, cell type was eliminated as
not having prognostic importance for recurrence-
free survival after including parameters that were
statistically significant. It should also be noted that
nodal status was considered universally (i.e., N1 and
N2 status).
As seen in Fig. 1, a preoperative volume of 100 cc
or more was associated with a significantly worse
prognosis compared with a preoperative volume less
than 100 cc (11 vs 22 months, p2 5 0.03). Preoper-
ative tumor volume also influenced the time to first
recurrence, be it local or systemic (Fig. 2). No
difference was observed between the postoperative,
Fig. 2. Influence of preoperative size on progression-free survival of patients having cytoreduction for
malignant pleural mesothelioma (p2 5 0.02)
Fig. 3. Influence of residual tumor volume after cytoreduction on overall survival of patients having
cytoreduction for malignant pleural mesothelioma (p2 5 0.0002)
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 2
Pass et al. 3 1 3
pre-CIT residual tumor volumes comparing patients
who received a pleurectomy decortication or EPP
(44 6 21 vs 28 6 10 cc, p2 5 0.62). However, the
volume of residual tumor, independent of the oper-
ation performed, influenced subsequent recurrence
and survival. Patients left with a residual solid tumor
volume (Fig. 3) of 9 cc or more had a significantly
decreased time to recurrence (p2 5 0.001) and a
median survival (Fig. 4) of 9 months compared with
25 months for patients with less than 9 cc residual
volume (p25 0.0002).
Most of the 47 patients (32, 68%) in this series
were found to have disease metastasized to the hilar
(N1) or mediastinal (N2) nodes, and the tumor
volumes for patients not having nodal metastases
were significantly smaller than for those patients
with N1 and/or N2 nodal metastases (108 6 27 vs
335 6 70 cc, p2 5 0.009, respectively). Moreover, the
presence or absence of either N1 or N2 disease was
correlated with preoperative size (Table I).
All 48 patients who had cytoreduction were
pathologically staged according to the IMIG staging
system. There were four stage I patients, four stage
II patients, 38 stage III patients, and two stage IV
patients. Because of this lack of equal distribution of
stages, a graded, stage by stage, decrease in survival
was not seen. Fig. 5 illustrates, nevertheless, that
stage grouping of I/II had a significantly better
survival than stage grouping III/IV (p2 5 0.006). As
depicted in Table II, the median preoperative sizes
(i.e., T status) correlated well with the actual post-
operative IMIG staging. There was a progressive,
significant trend (p2 5 0.007) in tumor volume as
postoperative IMIG stage increased from I to IV.
The results of multivariate analysis using the Cox
model are depicted in Tables III and IV. Male sex,
high platelet count, and large preoperative and
postcytoreduction tumor volumes predicted de-
creased survival and increased chance for recur-
rence. A moderate correlation was found between
platelet count and tumor volume (r2 5 0.53).
Because of the unavailability of the Voxell at all
institutions that may need accurate tumor estima-
tions, we attempted to validate the volumetrics using
a more labor intense, classic method to estimate the
Fig. 4. Influence of residual tumor volume after cytoreduction on progression-free survival of patients
having cytoreduction for malignant pleural mesothelioma (p2 5 0.001).
Table I. Correlation of preoperative tumor volume






N1 negative 11 74
0.01
N1 positive 17 391
N2 negative 18 70
0.04
N2 positive 29 163
No positive nodes 15 51
0.009
Any positive nodes 32 166
*Only pneumonectomies (n 5 25) and pleurectomy/lobectomy (n 5 3) had
N1 data; all 47 patients had mediastinal nodal dissections.
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area of solid tumor. Fig. 6 demonstrates that a 0.91
correlation existed between preoperative volume
estimates and the sum of the products of the per-
pendicular diameters on the individual computer-
ized tomographic slices for 43 patients.
Discussion
This study attempted to define whether T status in
terms of computerized tomographic volumetric
units was associated with (1) survival/recurrence for
patients having cytoreductive surgery for MPM, (2)
nodal involvement either intramediastinal or extra-
mediastinal, or (3) postoperative IMIG stage. All
data were prospectively entered on patients who
participated in a single trial at our institution over a
3-year period. We previously reported that the two
groups were similar with regard to preoperative and
postoperative volume measurements, and median
survival and recurrence data did not differ between
the groups, despite an additional therapy in one arm
(PDT).5 We felt justified, therefore, in combining
both groups as a single database to draw conclusions
on the influence of T status in MPM.
It would seem obvious what the results of this
study would be (i.e., the larger the size of the tumor,
the more decreased the chance of long-term surviv-
al). The model on which this premise could be based
Fig. 5. IMIG stage after cytoreduction staging and survival of patients with malignant pleural mesothe-
lioma (p2 5 0.006).
Fig. 6. Correlation of volumetric “T” status with stan-
dard “T” sizes as the sum of the products of the perpen-
dicular diameters for each computerized tomographic
slice (see text for details).
Table II. Association between preoperative volume











p2 5 0.007 I vs II vs III vs IV by Jonckheere test.
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is lung cancer. A fundamental difference exists,
however, between lung cancer and mesothelioma.
Size can be well defined with lung cancer if the
lesion is visible on plain chest x-ray film or comput-
erized tomogram without associated atelectasis or
effusion. It becomes more difficult, despite advances
in radiographic techniques, to apply more subjective
qualifiers to lung cancer T status (i.e., chest wall or
mediastinal invasion). With mesothelioma, no tech-
niques have been described that objectively define T
status as a size, and all T status qualifications in the
IMIG system are postoperative pathologic descrip-
tors that put great weight on invasiveness: what is
invaded, how deep or extensive is the invasion. Most
thoracic surgeons are not going to be willing to
provide a definitive answer to these descriptors in
the mesothelioma patient, especially those with
more bulk solid tumor than fluid, because they
simply are not going to explore the patient for the
resection of the disease. Therefore the more sober-
ing and perhaps important portion of the data
described here has to do with the predictive power
of computerized tomographic volumetrics on lymph
node status and overall stage of the disease.
Both N1 and N2 nodal tumor involvement could
be correlated with increasing size of the tumor. To
determine the exact cut off for size that would lead
one to predict that the nodes are involved, a larger,
prospective study is probably needed. However, it is
curious that the cutoff size for involvement of the N2
nodes in this study is smaller than the cutoff size for
involvement of the N1 nodes and probably reflects a
reverse situation to that seen in most lung cancers.
This would imply that the involvement of N1 nodes
in MPM has a graver prognostic implication than
the involvement of N2 nodes. For the 28 patients in
our series who had N1 nodes recorded pathologi-
cally, a trend toward increased survival (p2 5 0.072)
was observed if the nodes were free from tumor.
It is difficult to make definitive statements regard-
ing substantiation of the new IMIG staging system
for MPM from this study because a proclivity exists
for higher stage patients registered. Nevertheless,
the median survival of stage III disease of 11 months
compares favorably with that published by Rusch
and Venkatraman (11.5 months).4 Furthermore, it
appears that the size of the tumor is predictive of the
postoperative stage.
How can one explain the close correlation of T
status with staging in this disease? One could spec-
ulate that unlike other thoracic malignancies, the
biologic natural history of mesothelioma is one of
local progression without metastases until late in the
stage of the disease. This explains why certain
investigators have commented on the fact that pa-
tients who have EPP will usually die from systemic
rather than local disease. Therefore there seems to
be a biologic size threshold that may be influenced
by the local environment (i.e., stomal and matrix
issues, growth factor elaboration) above which local
factors can no longer prevent dissemination. This
would imply that the biologic diversity of mesothe-
lioma is more predictable (i.e., a smaller degree of
differentiation heterogeneity resulting in a plethora
of possible grades) than lung cancer.
Obviously other factors are involved with aggres-
siveness and predictability of mesothelioma other
than size. One simply has to refer to the Cox model








Male sex 2.41 0.0001 11.09 (3.22, 38.50)
Platelet count .314,000 1.12 0.0016 3.06 (1.24, 7.59)
Preoperative volume .100 cc 1.18 0.026 3.25 (1.15, 9.20)
Postoperative volume .9 cc 1.27 0.0042 3.55 (1.50, 8.47)








Male sex 1.65 0.0004 5.21 (2.11, 12.83)
Platelet count .268,000 1.27 0.0041 3.56 (1.50, 8.44)
Preoperative volume .52 cc 1.01 0.023 2.74 (1.16, 6.50)
Postoperative volume .9 cc 0.81 0.020 2.24 (1.13, 4.46)
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and see that sex and platelet number also indepen-
dently contribute to outcomes. The Cox model
clearly indicates that men are at a much greater risk
of dying (relative risk of 11.09) or having a recur-
rence (relative risk 5 5.21) than women. The Cox
model results indicate that both gender and size
each contribute, independently and substantially, to
the probability of dying or recurrence over time. In
other words, regardless of gender, tumor size is
important in prognosis, and, for any given tumor
size, gender is important in prognosis.
These findings regarding the implications of size
and prognosis in MPM need to be prospectively
verified in larger groups of patients. It is reasonable
to substitute a more quantitative “area” method to
estimate size as described with the four-quadrant
single-slice calculation, which correlated with our
computed tomographic volumetrics. This will save
cost but increase the time to calculate T status. Not
only will such an endeavor possibly give more pre-
cise prognostic information without pathologic ver-
ification, but it may also be useful in delineating
responses to nonsurgical (i.e., chemotherapy, immu-
notherapy, radiation, or gene therapy) treatments.
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Discussion
Dr. Larry R. Kaiser (Philadelphia, Pa.). Dr. Pass, first at
the National Cancer Institute and now in Detroit, has
been one of the real leaders in the search for new
knowledge and understanding of malignant mesotheli-
oma. We all owe him a sincere debt of gratitude. Several
years ago when we began working with this tumor, it was
Dr. Pass that we called on.
One of the real problems in assessing efficacy of any
therapy in this patient population has been the difficulty in
evaluating the extent of the disease. This tumor does not
lend itself to standard imaging modalities, and therapeutic
trials have suffered. Dr. Pass has just reported on a
technique that should allow us to significantly improve our
ability to assess preoperative stage and thus make it
possible for us to better assess efficacy of therapeutic
interventions. This is a major step forward. It behooves
those centers interested in treating mesothelioma—and
there are painfully few of those it seems—to avail them-
selves of the Voxell volumetric technique, although the
more work-intensive calculation of tumor areas provides a
reasonable approximation. The bottom line, however, is
that preoperative tumor volume correlates well with over-
all survival and validates the “T” component as important
in the staging of this disease.
I have several questions for Dr. Pass. Was the decision
to proceed with EPP versus pleurectomy/decortication
based solely on preoperative tumor size or was this a
decision made at the time of operation once the findings
were noted? If so, does this increased tumor size alone
account for the better survival seen in the lesser resection
group?
I was somewhat surprised by the high incidence of
lymph node involvement. Do you attribute this to the
performance of a mediastinal lymph node dissection in all
cases? Was mediastinoscopy performed? Would you have
proceeded with EPP if mediastinoscopy had been posi-
tive? Was there any perioperative mortality in the EPP
group? Your observations, perhaps, should make us re-
think our approach to EPP, although you have also told us
that the less tumor that remains postoperatively, the
better the survival.
I am also a little bit confused about your postoperative
measurements. If maximal debulking was carried out such
that there was no gross residual disease, how was it
possible to perform volume measurements or was the
postoperative volume assessed at the time of operation?
Where were the most common areas where tumor re-
mained? Did you not take hemidiaphragm and pericar-
dium in all pneumonectomy cases? Why, if less postoper-
ative tumor correlates with improved survival, did all
patients not have EPP? Finally, how would you propose
that we make maximum use of the information that you
have presented today?
Dr. Malcolm M. DeCamp (Boston, Mass.). Quantitating
the tumor volume is a very difficult thing, and I think you
have taken a very important step. We have been using
magnetic resonance imaging scans to look at coronal,
sagittal, and axial planes to evaluate areas of bulk disease.
It helps us determine resectability and who may be a
better candidate for pneumonectomy versus pleurectomy.
I wonder whether your technique could be applied in the
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other tissue planes to give an even more accurate assess-
ment of tumor bulk?
Dr. Pass. I would like to thank the discussants for their
thoughtful questions.
The decision about EPP or pleurectomy was not made
beforehand, but in the operating room. I would tell the
patient that there is a chance that they may have an EPP
and give them a percentage, but I let the findings at the
operation dictate what I do.
The lymph node involvement is indeed different in our
series. As opposed to other series that report 21-month
median survivals, which are very carefully staged, we had
67% to 70% of our patients with positive nodes, which is
very similar to what Valerie Rusch has reported in her
LCSG experience, as well at Sloan-Kettering.
Considering now that I have done the curves and that
there seems to be a trend that lymph node disease may be
important in this, and Dr. Rusch has also shown that, I
think that mediastinoscopy is not a bad idea in these
patients considering that there will be therapies coming
on-line that may be less toxic for possible induction
therapies for these patients.
Sights of residual tumor are mainly on the diaphragm.
The difference between my resections and other resec-
tions are that I do a “modified” EPP and that I do not
commit the patient to the removal of the diaphragm. If I
believe that I can get down to 5 mm by either going
through the diaphragm or taking portions of the dia-
phragm, I do that, and then I will reconstruct the dia-
phragm to itself or with polytetrafluoroethylene. A posi-
tive margin is a positive margin wherever it is, and that is
the way I have dictated my cases with mesothelioma.
In this particular series, the randomized trial, there was
one mortality. So the total is 1 of 48.
With regard to magnetic resonance imaging scans, I
think magnetic resonance imaging scans are very, very
useful, and I think magnetic resonance imaging scans
may dictate whether you have to use invasive ways of
staging, as Dr. Rusch has talked about, using either
laparoscopy or thoracoscopy in looking under the dia-
phragm. Volume assessment is just going to give you a
number and not comment on invasiveness or biologic
characteristics. That is the one limitation of volume
measurements.
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